| Document |
Document Title |
|
WO/2020/134138A1 |
The present disclosure relates to the technical field of luminescent materials, and relates in particular to an organic electroluminescent compound, a preparation method therefor and an organic electroluminescent device. In order to solv...
|
|
WO/2020/131689A1 |
Provided herein is a compound of Formula (I), or a salt thereof, wherein R1 is a moiety having the following structure: (II) wherein Z is selected from the group consisting of O and N; X is selected from the group consisting of a bond, N...
|
|
WO/2020/127259A2 |
The present application concerns compounds for use in electronic devices, processes for preparing the compounds, and electronic devices comprising the compounds.
|
|
WO/2020/127194A1 |
Anticancer compounds of formula (I) and derivatives thereof are provided.
|
|
WO/2020/132278A1 |
The present invention concerns the use of compounds and compositions for the treatment or prevention of Flavivirus infections, such as dengue virus infections and Zika virus infections. Aspects of the invention include methods for treati...
|
|
WO/2020/127200A1 |
The present invention relates to a compound of formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof Formula (I) and to pharmaceu...
|
|
WO/2020/130102A1 |
Antibody preparations for improving or treating autoimmune diseases have been proposed, but the route of administration is limited to intravenous, imposing a burden on the patient. Also, mangiferin has an effect for improving autoimmune ...
|
|
WO/2020/120528A1 |
The present invention provides the compounds having the general formula: (I) wherein R1 to R8, and X are as described herein, compositions including the compounds and methods of using the compounds.
|
|
WO/2020/122908A1 |
An electrochromic medium for use in an electro-optic device comprises a solvent comprising at least one low-volatile organic electrolyte solvent based on a cyclic carbonate ester; an anodic electroactive material; and a cathodic electroa...
|
|
WO/2020/117894A1 |
Enantioselective total syntheses of the anticancer isocarbostyril alkaloids (+)-7-deoxypancratistatin, (+)-pancratistatin, (+)-lycoricidine, and (+)-narciclasine are described. Our strategy for accessing this unique class of natural prod...
|
|
WO/2020/118116A1 |
The present disclosure provides NIR- and SWIR-active small molecule polymethine dyes with improved properties for use in optical imaging, photothermal therapy, and photodynamic therapy.
|
|
WO/2020/110008A1 |
The disclosure relates to inhibitors of PCSK9 useful in the treatment of cholesterol lipid metabolism, and other diseases in which PCSK9 plays a role, having the Formula (I):, or a pharmaceutically acceptable salt, hydrate, solvate, prod...
|
|
WO/2020/111613A1 |
The present invention provides a novel compound and an organic light-emitting diode using same.
|
|
WO/2020/111602A1 |
The present invention provides a novel compound and an organic light-emitting element using same.
|
|
WO/2020/111586A1 |
The present invention provides a novel compound and an organic light-emitting device using same.
|
|
WO/2020/111584A1 |
The present invention provides a novel compound and an organic light emitting diode using same.
|
|
WO/2020/111601A1 |
The present invention provides a novel compound and an organic light-emitting device using same.
|
|
WO/2020/111780A1 |
The present invention provides a novel compound and an organic light emitting device using same.
|
|
WO/2020/111585A1 |
The present invention provides a novel compound and an organic light-emitting device using same.
|
|
WO/2020/111673A1 |
The present invention provides a novel compound and an organic light emitting diode using same.
|
|
WO/2020/111225A1 |
Provided are: a triazine compound having a high glass transition temperature, the triazine compound contributing to the formation of an organic electroluminescent element that exhibits high luminous efficiency and long service life chara...
|
|
WO/2020/106028A1 |
The present specification provides a compound represented by chemical formula 1 and an organic light-emitting device comprising same.
|
|
WO/2020/106102A1 |
The present specification relates to a compound of chemical formula 1 and an organic light emitting diode comprising same.
|
|
WO/2020/087694A1 |
The present invention relates to a substituted nitrogen-containing heterocyclic formamide derivative, a weeding composition and the uses thereof. The substituted nitrogen-containing heteroaromatic ring formamide derivative has a structur...
|
|
WO/2020/091446A1 |
The present disclosure relates to an organic electroluminescent compound and an organic electroluminescent device comprising the same. By comprising the organic electroluminescent compound according to the present disclosure, an organic ...
|
|
WO/2020/085797A1 |
The present invention relates to a compound for an organic electric element, an organic electric element using same, and an electronic device thereof. According to the present invention, high light-emitting efficiency, low driving voltag...
|
|
WO/2020/085845A1 |
The present disclosure relates to an organic electroluminescent compound and an organic electroluminescent device comprising the same. The organic electroluminescent compound of the present disclosure may be comprised in a light-emitting...
|
|
WO/2020/079173A1 |
The present disclosure relates to fungicidal active compounds, more specifically to pyridylphenylaminoquinolines and analogues thereof, processes and, intermediates for their preparation and use thereof as fungicidal active compound, par...
|
|
WO/2020/073985A1 |
The invention provides a crystalline structure of mu opioid receptor (MOR) agonist and a preparation method therefor. Specifically, the invention provides (1S4S)-4-ethoxy-N-(2-((R)-9-(pyridine-2-yl)-6-oxaspiro [4.5] decano-9-yl) ethyl) -...
|
|
WO/2020/070088A1 |
The present invention provides novel compounds having the general formula (Formula I) : wherein R1 to R6, G1, G2, A1 to A4 and m are as described herein, compositions including the compounds and methods of using the compounds.
|
|
WO/2020/071550A1 |
The present invention provides a novel CDK8 inhibitor. The present invention relates to: a compound represented by general formula (I) (wherein the symbols are as defined in the description) or a pharmaceutically acceptable salt thereof;...
|
|
WO/2020/072695A1 |
3-Carbonylamino-8-aminoisoquinoline compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an ...
|
|
WO/2020/067457A1 |
The objective of the present invention is to provide a compound which may be useful for preventing or treating constipation or the like. The present invention provides a compound represented by formula (I) [each symbol in the formula is ...
|
|
WO/2020/067456A1 |
The objective of the present invention is to provide a compound which may be useful for preventing or treating constipation or the like. The present invention provides a compound represented by formula (I) [in the formula, R1 represents ...
|
|
WO/2020/065642A1 |
The present invention provides new GABAA receptor-binding compounds that modify the activation of GABAA, their use in in the preparation of a neuroactive pharmaceutical composition, improving sperm motility and labeling of biomolecules.
|
|
WO/2020/058160A1 |
The present invention relates to methods for controlling or preventing infestation of cereal plants by the phytopathogenic microorganism Fusarium pseudograminearum, comprising applying to a crop of plants, the locus thereof, or seed ther...
|
|
WO/2020/058339A1 |
Disclosed herein are novel coumarin-based reagents, e.g. linkers, and conjugates including one or more of the disclosed coumarin-based reagents. In some embodiments, the presence of a coumarin moiety within the coumarin-based reagents en...
|
|
WO/2020/055725A1 |
Disclosed herein are novel methods of treating pain in a patient in need thereof by providing to the patient a selective dopamine D3 receptor antagonist/partial agonist which when used with an opioid analgesic, can mitigate the developme...
|
|
WO/2020/045924A1 |
The present invention provides a novel compound and an organic light emitting diode using same. More specifically, the present invention provides a compound represented by chemical formula 1 below, and an organic light emitting diode com...
|
|
WO/2020/043821A1 |
The present invention is directed to furan derivatives, pharmaceutical compositions comprising the compounds and the use of the compounds or the compositions in the treatment of various diseases.
|
|
WO/2020/039092A2 |
The present invention comprises novel aromatic molecules, which can be used in the treatment of pathological conditions, such as cancer, skin diseases, muscle disorders, and immune system-related disorders such as disorders of the haemat...
|
|
WO/2020/039088A2 |
The present invention comprises novel aromatic molecules, which can be used in the treatment of pathological conditions, such as cancer, skin diseases, muscle disorders, and immune system-related disorders such as disorders of the haemat...
|
|
WO/2020/040591A1 |
The present invention relates to a novel use of a pyrimidine derivative comprising an LRRK kinase inhibitor as an effective ingredient. A pharmaceutical composition, provided according to one aspect of the present invention, for preventi...
|
|
WO/2020/033520A1 |
The present invention provides compounds of Formula (I) useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders, wherein each of Ring A, L, Q, R1, R2, R3, R4, R7, and R8 along with other variabl...
|
|
WO/2020/031107A1 |
The invention is directed to substituted tetrahydrofuran derivatives. Specifically, the invention is directed to compounds according to Formula (I), wherein C, D, L1, L2, R1, R2, R3, R4, R5, R6, Y1, Y2, z1, z2, z3, z4, X1, X2, X3, X4, X5...
|
|
WO/2020/026054A1 |
The compositions and compounds of formula I and formula II which includes nucleic acid synthesis inhibitor conjugates or its polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These conjugates may be formulated as ph...
|
|
WO/2020/025030A1 |
Provided are an aromatic compound having immunoregulatory effect, a preparation method thereof, and a use of the same in regulating immune responses or inhibiting PD-1/PD-L1.
|
|
WO/2020/021953A1 |
Provided is a composition for optical materials that gives optical materials which can have at least one improved property selected from among satisfactory mold releasability after polymerization and curing, unsusceptibility to separatio...
|
|
WO/2020/021113A1 |
The invention relates to a process to prepare a compound of the following formula (I): (I), in which P represents a protective group of a hydroxyl function which is a -COR1 group with R1 representing an aryl or a (C1C6)alkyl, R represent...
|
|
WO/2020/015675A1 |
The present invention belongs to the technical field of semiconductors. Disclosed are a compound having triarylamine as a core and an application thereof. The structure of the compound provided in the present invention is represented by ...
|
